Physician profile
John M Thomas
NPI 1730289877
$4,197.81
in general payments reported to CMS, 2019-2025
43 companies · $935 in 2025
The $935 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $102 · 2021: $488 · 2022: $521 · 2023: $900 · 2024: $715 · 2025: $935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,549.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $409.88 | 2019-2025 | Ofev, Jardiance |
| Abbvie INC. | $310.30 | 2020-2025 | Vraylar |
| Novo Nordisk INC | $210.53 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $209.11 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $206.62 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $197.03 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $194.01 | 2019-2025 | Gardasil 9, Verquvo, Vaxneuvance |
| Teva Pharmaceuticals USA, INC. | $171.36 | 2019-2025 | Austedo Xr, Airduo Digihaler |
| Pfizer INC. | $156.96 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $151.63 | 2019-2025 | Spravato |
| Amgen INC. | $142.81 | 2019-2025 | Otezla, Repatha, Evenity |
| Astellas Pharma US INC | $134.85 | 2022-2024 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $134.82 | 2023-2025 | Nuedexta, Rexulti |
| Corcept Therapeutics | $115.83 | 2023-2025 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $106.83 | 2020-2025 | Eliquis, Camzyos |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.